ZBH Price Prediction Next Week
Technical Analysis: Based on the latest price data, ZBH closed at $100.52 on February 14, 2025, with a 0.61% gain. The stock has been showing bearish momentum, trading below its key moving averages.
News and Event Analysis:
- Recent Q4 2024 earnings report showed adjusted EPS of $2.31, beating expectations, but the stock declined 5.1% following the release
- The company's FY25 outlook was weaker than expected, pressuring the stock price
- Multiple analysts have recently lowered their price targets:
- Truist Financial lowered from $118 to $113
- RBC Capital lowered from $130 to $125
- Raymond James lowered from $126 to $119
Price Prediction for Next Week: Based on technical indicators and recent news sentiment:
- Support level: $97.69 (52-week low)
- Resistance level: $101.90 (recent high)
Expected price range: $98.50 - $102.00
Trading Recommendation: SELL Rationale:
- Weak technical momentum with stock trading below moving averages
- Analyst concerns about FY25 outlook
- Stock has underperformed both S&P 500 and medical device sector, down 18.9% over past year
- Conservative organic revenue guidance of 3-5% for 2025 below analyst expectations
Target exit price: $98.50
The stock appears to be in a downtrend with limited upside potential in the near term. The conservative guidance and analyst downgrades suggest continued pressure on the stock price. While there may be some product launches in H2 2025 that could support growth, the near-term technical and fundamental picture remains bearish.
ZBH Similar Chart Price Prediction
The price of ZBH is predicted to go up 6.84%, based on the high correlation periods with VNOM. The similarity of these two price pattern on the periods is 97.63%.
ZBH
VNOM
Up: 6.84%Similarity: 97.63%
ZBH Revenue Forecast
ZBH EPS Forecast
ZBH FAQs
What is bull’s view on ZBH?
What is bear's view on ZBH?
What is ZBH revenue forecast for next quarter？
What is ZBH eps forecast for next quarter？
ZBH VS S&P500
Zimmer Biomet has made impressive progress in placing its Rosa robots in hospitals and ambulatory surgical centers, paving the way for higher-margin implant pull through.
Orthopedic surgeons often resist efforts by hospitals or health systems to limit their autonomy (and brand choice), which is one major factor that has contributed to the consistent failure of most programs put forth by providers.
Zimmer has amassed an impressive portfolio of patents, owning or controlling approximately 4,500 issued patents and applications worldwide.
ZBH Analyst's Forecast
Matt Miksic
Barclays
Sell
2025-02-10
Price Target
$118 → $112
Upside
+11.53%
Barclays lowered the firm's price target on Zimmer Biomet to $112 from $118 and keeps an Underweight rating on the shares. The firm updated its projections to be in-line with Zimmer's 2025 outlook.
Rick Wise
Stifel
Strong Buy
2025-01-23
Price Target
$130 → $138
Upside
+24.31%
Richard Newitter
Truist Securities
Hold
2024-12-18
Price Target
$117 → $118
Upside
+11.47%
